Sign inJoin waitlistJoin the waitlist

Oliver Press

Pathology / Anatomic Pathology & Clinical Pathology

Credentials: · · · ·

History

Cytopathology
University of Southern California/Los Angeles General Medical Center
2015–2016
Pathology-Anatomic and Clinical
University of Southern California/Los Angeles General Medical Center
2011–2015
University of Southern California/Los Angeles General Medical Center
2010–2011
Keck School of Medicine of USC
2006–2010

Research

Impact of induction regimen and stem cell transplantation on outcomes in double-hit lymphoma: a multicenter retrospective analysis
Blood · 2014 · 391 citations
Obinutuzumab plus bendamustine versus bendamustine monotherapy in patients with rituximab-refractory indolent non-Hodgkin lymphoma (GADOLIN): a randomised, controlled, open-label,…
The Lancet Oncology · 2016 · 285 citations
NCCN Clinical Practice Guidelines in Oncology: non-Hodgkin's lymphomas
Journal of the National Comprehensive Cancer Network · 2010 · 233 citations

AZ
Andrew Zelenetz
16 papers
Julie Vose
14 papers
Leo Gordon
13 papers
Ranjana Advani
13 papers
Ann LaCasce
12 papers
JA
Jeremy Abramson
12 papers
Joachim Yahalom
12 papers
JB
John Byrd
12 papers
Luis Fayad
12 papers
MG
Martha Glenn
12 papers
Pierluigi Porcu
12 papers
Richard Hoppe
12 papers

Clinical trials

Feasibility of Assessing Lymphoma Response to Precise Local Injection of Candidate Chemotherapy Agents
Principal investigator · Completed · Phase 1
Presage Biosciences
2012–2013
Long-Term Effects of Iodine I Tositumomab and Autologous Bone Marrow or Stem Cell Transplantation in Patients With Relapsed or Refractory Non-Hodgkin's Lymphoma
Principal investigator · Completed
Fred Hutchinson Cancer Center
2002–2011
S0816 Fludeoxyglucose F 18-PET/CT Imaging and Combination Chemotherapy With or Without Additional Chemotherapy and G-CSF in Treating Patients With Stage III or Stage IV Hodgkin Lymphoma
Study chair · Completed · Phase 2
SWOG Cancer Research Network
2009–2022
S0801 Iodine I 131 Tositumomab, Rituximab, and Combination Chemotherapy in Previously Untreated Stage II, Stage III, or Stage IV Follicular Non-Hodgkin Lymphoma
Study chair · Completed · Phase 2
SWOG Cancer Research Network
2009–2019